King & Spalding has continued to expand its patent litigation offering, advising technology, life sciences and manufacturing clients on high-value patent infringement disputes, trade secret litigation and Section 337 investigations before the US International Trade Commission. The team has secured notable successes for clients including Motive Technologies, CG Oncology, F5, TCL Electronics and Composite Resources, reflecting its strength in complex, business-critical IP disputes. Washington DC-based practice co-head Stephen Baskin is a seasoned first-chair trial lawyer with extensive experience in high-stakes technology litigation, while fellow co-head Neel Chatterjee, based in Silicon Valley, has strengthened the firm’s West Coast offering since joining in 2025 and is a key contact for cutting-edge patent, trade secret and commercial technology disputes. Washington, DC-based Dara Kurlancheek is recognized for her expertise in complex patent litigation and licensing matters, while Denver-based Angela Tarasi is recommended for technology-focused patent disputes, having led a number of significant mandates for clients in the software and life sciences sectors. Washington, DC-based Jeffrey Telep is a prominent name for Section 337 investigations and ITC proceedings, further strengthening the firm’s nationwide IP litigation capabilities.
Legal 500 Editorial commentary
Key clients
- F5, Inc.
- Motive Technologies
- CG Oncology
- LKQ Corporation
- Transcore
- Composite Resources Inc. and North American Rescue LLC
- Modumetal
- TCL Electronics
Work highlights
Secured a complete defense verdict for Motive Technologies, a leading AI-powered fleet management and driver safety platform, in a high-stakes, bet-the-company competitor case. Plaintiffs - Omnitracs, XRS, and SmartDrive - alleged that Motive’s Vehicle Gateway and AI Dashcam products infringed patents covering fleet management, video, and analytics technologies, seeking over $100 million in damages and injunctive relief that would have impacted much of Motive’s product line.
Secured a complete defense verdict for CG Oncology, Inc. in a high-stakes Delaware jury trial brought by ANI Pharmaceuticals, Inc. ANI sought a declaration of entitlement to running royalties on future sales of CG Oncology’s investigational bladder cancer therapy, cretostimogene, or alternatively $2.3 billion in unjust enrichment damages related to non-patent assets acquired by CG Oncology’s predecessor in 2010.
The U.S. International Trade Commission issued its final decision in the section 337 investigation on Certain Blood Flow Restriction Devices With Rotatable Windlasses, Inv. No. 337-TA-1364, in favor of Composite Resources (“CRI”) and North American Rescue (“NAR”), the sole US producer and exclusive US distributor, respectively, of combat application tourniquets.
Practice head
Stephen Baskin; Neel Chatterjee
Other key lawyers
Dara Kurlancheek; Angela Tarasi; Jeffrey Telep